Sankyo Implements SAS Solution for Drug Development

SAS Institute Japan announced March 9 that Sankyo, one of Japan's leading pharmaceuticals, has adopted SAS Drug Development (SDD), SAS's proprietary solution designed for the pharmaceutical industry which helps streamline the entire drug development process. Aiming for a substantial reduction in its R&D process as well as improved productivity, Sankyo will use SDD for data analysis including nonclinical studies.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9572)